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eIF4E, the mRNA 50 cap-binding translation initiation factor, is overexpressed in numerous cancers and is
implicated in mechanisms underlying oncogenesis and senescence. 4E-BPs (eIF4E-binding proteins) inhibit
eIF4E activity, and thereby act as suppressors of eIF4E-dependent pathways. Here, we show that tumorigen-
esis is increased in p53 knockout mice that lack 4E-BP1 and 4E-BP2. However, primary fibroblasts lacking
4E-BPs, but expressing p53, undergo premature senescence and resist oncogene-driven transformation.
Thus, the p53 status governs 4E-BP-dependent senescence and transformation. Intriguingly, the 4E-BPs
engage in senescence via translational control of the p53-stabilizing protein, Gas2. Our data demonstrate
a role for 4E-BPs in senescence and tumorigenesis and highlight a p53-mediated mechanism of senescence
through a 4E-BP-dependent pathway.INTRODUCTION
Translation initiation is deregulated during tumorigenesis
(Schneider and Sonenberg, 2007). The translation initiation fac-
tor, eIF4E, is an oncogene that regulates the translation of a
specific subset of tumor-promoting mRNAs (Graff et al., 2007;
Mamane et al., 2007; Schneider and Sonenberg, 2007). eIF4E,
like other oncogenes (e.g., Akt or Ras) induces senescence,
which acts as an intrinsic barrier to cancer (Campisi and
d’Adda di Fagagna, 2007; Collado et al., 2007; Lowe et al.,
2004). Loss of tumor suppressors (e.g., p53 and p19ARF) impairs
senescence and promotes cell transformation (Miyauchi et al.,
2004; Nogueira et al., 2008; Serrano et al., 1997). Because
eIF4E activity is negatively regulated by the eIF4E-binding
proteins (4E-BPs), we reasoned that eIF4E-induced senescenceCmay be regulated by 4E-BPs. Here, we describe the translational
control of senescence and transformation by 4E-BPs.
RESULTS
To assess the role of 4E-BPs in tumorigenesis in vivo, we com-
pared tumor-free survival of p53/ with 4E-BP1/ 4E-BP2/
p53/ triple knockout (TKO) mice. As shown previously, p53/
mice exhibited a high incidence of tumors, especially lym-
phomas (Donehower et al., 1992), with a mean tumor-free
survival time of 23 weeks. TKO mice developed similar types
of tumors, but the tumor-free survival was reduced (15 versus
25 weeks; p < 0.001), as compared with p53/mice (Figure 1A).
Interestingly, the survival of p53+/mice was not reduced by the
absence of 4E-BPs (see Figure S1 available online), suggestingSIGNIFICANCE
Mounting evidence shows that eIF4E is an important oncogene, which is currently a target for anticancer drugs in clinical
trials. Poor prognosis correlates with increased eIF4E expression levels and increased phosphorylation of its major cellular
inhibitor, 4E-BP1. Cells lacking 4E-BPs undergo p53-dependent senescence and are resistant to oncogenic transformation.
This phenomenon is explained by the translational control of Gas2 expression. These genetic data demonstrate that
targeted disruption of 4E-BP expression causes elevated expression of the p53-tumor suppressor protein. Our findings
are significant for anticancer drug development because they show that the p53 status must be considered in studies of
therapeutic targeting of the translation initiation pathway.ancer Cell 16, 439–446, November 3, 2009 ª2009 Elsevier Inc. 439
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4E-BPs Regulate Senescence and TransformationFigure 1. 4E BPs Control p53 Dependent Senescence
(A) Kaplan Meier plot showing survival of p53 / and 4E BP1 / 4E BP2 / p53 / triple knockout (TKO) mice. Median survival: p53 / = 23 weeks (n = 19),
TKO = 15 weeks (n = 19); p < 0.001.
(B) Population doublings (PDs) for WT and DKOMEFs were determined for eight passages. MEFs from three independent pairs of embryos were examined. Error
bars indicate the standard deviation (SD).
(C) PDs were determined for DKO MEFs transduced with MSCV IRES GFP (vector), MSCV 4E BP1 IRES GFP, or MSCV 4E BP2 IRES GFP (n = 3).
(D) SA b gal positive cells (%) in WT, p53 / , DKO, and TKO MEF cultures at passages 4, 5, and 6. The average is shown for each genotype. Error bars indicate
the SD (n = 3).
(E) MRC5 cells infected with control lentivirus (shC) or with sh4E BP1 and sh4E BP2 lentiviruses together (shBP1/shBP2). SA b gal staining of MRC5 cells (day 4;
upper left) and western blots (lower left) showing 4E BP1 and 4E BP2 silencing. Quantification of % SA b gal positive cells (day 2; upper graph) and proliferation
(0 to 4 days; lower graph) are indicated in the graphs showing averages. Error bars represent SD (n = 3). WB, western blot.
(F) PDs for DKO MEFs transduced with p53shRNA or MSCV IRES GFP retroviruses (n = 3).
(G) PDs for DKO and TKO MEFs were determined for 8 passages. The values are an average of two independent experiments.
(H) Western blot analysis of p53, 4E BP1, and 4E BP2 expression levels inWT and DKOMEFs with varying p53 status (+/+, +/ , / ). b actin served as a loading
control. WB, western blot.that a role for 4E-BP in tumorigenesis varies depending on the
amount of p53 in the cell. These results demonstrate that in the
complete absence of p53, 4E-BPs increase tumor-free survival.440 Cancer Cell 16, 439–446, November 3, 2009 ª2009 Elsevier IncWe further studied the role of 4E-BPs in tumorigenesis using
primary murine embryonic fibroblasts (MEFs). The population
doubling rate of 4E-BP1/ 4E-BP2/ double knockout (DKO).
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4E-BPs Regulate Senescence and TransformationMEFs was reduced by 37% as compared with wild-type (WT)
MEFs. At passage 8, WTMEFs had undergone 22 ± 3 population
doublings (PDs), relative to 16 ± 2 PDs for DKOMEFs (Figure 1B).
Between passages 4 and 8, DKO MEFs also exhibited a > 50%
reduction in the number of cells in S phase, as compared
with WT MEFs (data not shown). To confirm the role of 4E-BPs
in the proliferative defect of DKO MEFs, 4E-BP1 or 4E-BP2
was re-expressed in DKO MEFs using retroviral vectors.
Expression of 4E-BP1 or 4E-BP2 in DKO MEFs engendered
faster growth beyond passage 6 (Figure 1C). These data demon-
strate that the slow growth of DKO MEFs is due to the lack of
4E-BPs.
Reduced growth of DKO MEFs could be caused by increased
cell death or senescence. Increased apoptosis was not ob-
served (data not shown). However, DKO MEFs exhibited a
2.5–fold increase in the number of cells staining positive for
senescence-associated b-galactosidase (SA-b-gal) activity, as
compared with WT MEFs (21.7% ± 2.2% versus 8.8% ± 1.8%,
p < 0.05) (Figure 1D). This finding is not restricted to MEFs,
because shRNA silencing of 4E-BP1 and 4E-BP2 in MRC-5
human lung fibroblasts caused morphological flattening, a
50% reduction in cell proliferation rate, and a 2-fold increase in
senescent cells (Figure 1E). Thus, the lack of 4E-BPs impedes
cell proliferation due to premature senescence. eIF4E overex-
pression in MEFs also induces senescence (Ruggero et al.,
2004), suggesting that these findings are caused by increased
eIF4E activity due to the absence of 4E-BPs.
Because p53 is a central regulator of senescence (Serrano
et al., 1997), we investigated whether increased senescence in
DKO MEFs was p53 dependent. Less than 2% of p53/ or
TKO MEFs (1.6% and 1.4%, respectively) exhibited SA-b-gal
activity (Figure 1D), demonstrating that p53 is required for DKO
MEFs to undergo senescence. For corroboration of these find-
ings, p53 was silenced in DKOMEFs, which reversed the growth
phenotype of DKO MEFs (Figure 1F). Furthermore, TKO MEFs
underwentmanymore PDs than DKOMEFs after eight passages
(Figure 1G; 29 PDs versus 13 PDs, respectively). Finally, p53
protein levels were increased by 1.5- and 2-fold in DKO MEFs
(p53+/+ and p53+/, respectively; passage 6), as compared
with p53+/+ and p53+/ MEFs, respectively (Figure 1H), demon-
strating that senescence correlates with increased p53 expres-
sion. Thus, DKO MEFs express elevated p53 protein levels and
undergo p53-dependent senescence.
p53-mediated senescence antagonizes tumorigenesis (Chen
et al., 2005; Deng et al., 2008; Lowe et al., 2004). To examine
whether the increase in p53-dependent senescence observed
in DKO MEFs renders these cells resistant to transformation,
MEFs were infected with a retrovirus expressing both E1A and
Ras proteins. E1A/Ras-expression in WT MEFs caused 2.5 ±
0.3 more focus formation than in DKO MEFs (Figure 2A). The
empty retrovirus or that expressing E1A alone failed to transform
cells (Figure 2A). Introduction of 4E-BP1 or 4E-BP2 into DKO
MEFs caused more than a 2-fold increase in the number of foci
formed when E1A and Ras were overexpressed (Figure S2).
Furthermore, E1A/Ras-expressing WT MEFs formed subcuta-
neous tumors in nude mice, whereas E1A/Ras-expressing
DKO MEFs failed to do so (Figure 2B). To determine whether
p53 expression levels modulated transformation, we compared
the effect of E1A/Ras in WT and DKO MEFs harboring varyingCamounts of p53 protein by using p53+/+, p53+/, and p53/
MEFs. Similar to the E1A/Ras-induced transformation rates in
WT and DKO MEFs, DKO (p53+/) MEFs formed 1.9- ± 0.4-fold
fewer foci as compared with p53+/ MEFs (Figure 2C). In con-
trast, both p53/ and TKO MEFs formed more than ten times
the number of foci observed in p53+/+ and p53+/ MEFs (Fig-
ure 2C). Consistent with the focus formation assays, p53-
expressing DKO MEFs (p53+/+ or p53+/) also formed 3-fold
fewer colonies in soft agar, as compared with WT MEFs (p53+/+
or p53+/MEFs) (Figure 2D). The reduction in the number of colo-
nies formed by DKO MEFs was not seen in the absence of p53
(Figure 2D). Retroviral transduction efficiency, as monitored by
Ras protein expression, was similar in all the MEFs examined
(Figure 2E). These results show that the transformation of
4E-BP1/4E-BP2/ DKO MEFs is impaired by the p53
pathway and loss of 4E-BPs enhances transformation in
p53/ cells.
Given the increase in p53 protein expression in DKOMEFs, we
wished to elucidate the molecular mechanism of p53 regulation.
p53 mRNA levels in primary WT and DKO MEFs were not
different (Figure S3). Furthermore, p53 mRNA translation rates
were similar in WT and DKO MEFs (see below and Figure 3D),
suggesting that p53 protein expression was controlled at a post-
translational level in DKOMEFs. Indeed, p53 protein stability was
increased in both primary and E1A/Ras expressing DKO MEFs,
as compared with WT MEFs (Figures S4A and S4B, respec-
tively). Neither p19ARF nor p16 protein levels increased in DKO
MEFs (Figure S4A), suggesting that p53 was stabilized indepen-
dently of changes in the p19ARF/Mdm2 pathway (Pomerantz
et al., 1998).
p53 can also be stabilized through the Gas2 protein, which
inhibits m-calpain, a calcium-dependent protease (Benetti
et al., 2001). Gas2mRNA and protein levels increase upon serum
withdrawal and diminish by serum stimulation (Benetti et al.,
2005; Schneider et al., 1988). To determine whether Gas2 pro-
tein levels are regulated by the 4E-BPs, we grew MEFs in low
serum (0.1%) for 24 hr and then stimulated them with 20%
serum. After 48 hr of stimulation, Gas2 protein levels decreased
by 75% in WT MEFs, as compared with unstimulated cells
(Figure 3A; comparing 0 and 48 hr). In contrast, DKOMEFsmain-
tained a high level of Gas2 protein, even after 48 hr of serum
stimulation when the level of Gas2 protein was approximately
5-fold higher, as compared with WT MEFs (Figure 3A). Serum
stimulation also caused an increase in p53 protein expression,
in agreement with earlier results (Reich and Levine, 1984). Con-
sistently, maintenance of high Gas2 protein levels upon serum
stimulation correlated well with elevated p53 protein levels
(>3-fold by 24 hr; Figure 3A). Gas2 mRNA levels decreased to
a similar extent (90% and 80%) in WT and DKO MEFs, respec-
tively (Figure S5A). Thus, Gas2 protein levels are elevated in
DKO MEFs primarily through a posttranscriptional process.
The regulation of Gas2 was also examined in p53/ and TKO
MEFs. Although serum stimulation caused a 90% decrease in
Gas2 mRNA levels in both p53/ and TKO MEFs (Figure S5B),
TKO MEFs expressed > 2-fold more Gas2 protein, as compared
with p53/ MEFs after 48 hr of stimulation (Figure 3B). Consis-
tent with the above data, actinomycin D treatment caused a
similar reduction in Gas2 mRNA levels in 4E-BP null and control
MEFs (Figure S6). Elevation of Gas2 protein in DKO MEFs isancer Cell 16, 439–446, November 3, 2009 ª2009 Elsevier Inc. 441
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Gas2 binding to m-calpain impairs its activity (Benetti et al.,
2001). Indeed, lower calpain activity (49% ± 7%, p < 0.05) was
detected in DKO MEF extracts (Figure 3C, upper panel).
Reduced calpain activity in DKO MEFs (51% ± 12%, p < 0.05)
was also detected in vivo using flow cytometry to monitor the
cleavage of the calpain-specific substrate, t-BOC-LM-CMAC
(Figure 3C, lower panel). Taken together, these data demon-
strate that Gas2 protein expression is controlled by 4E-BPs at
the posttranscriptional level.
Because 4E-BPs are translational regulators (Pause et al.,
1994), we assessed the translational efficiency of Gas2 mRNA
in 4E-BP DKO MEFs using sucrose gradients to partition effi-
ciently translated mRNAs (enriched on polysomes) from poorly
translated mRNAs. Heavy sedimenting polysome fractions
from DKO MEFs contained 1.94 ± 0.5 (p < 0.05) more Gas2
mRNA than WT MEFs (Figure 3D). In contrast, the polysome
distribution of p53 and p19ARF mRNAs was not altered in DKO
MEFs (Figure 3D). Thus, the elevated levels of Gas2 protein in
DKO MEFs are caused by a selective increase in translational
initiation of Gas2 mRNA, most likely mediated by an increase
in eIF4E activity because of the absence of 4E-BPs. Consistent
with this notion, eIF4E overexpression caused an increase in
Gas2 protein (Figure S7). Taken together, these data demon-
strate that DKO MEFs express more Gas2 protein as a result
of an increase in Gas2 mRNA translation initiation.
Figure 2. Loss of 4E BP Expression Renders MEFs Resistant to E1A/Ras Induced Transformation in a p53 Dependent Manner
(A) Focus formation assay showing WT and DKO MEFs at 2 weeks after infection with retroviruses (pLPC [empty control vector], E1A, or E1A/Ras) (n = 4).
(B) Tumor growth of E1A/Ras expressingWT (left, arrow) and DKO (right) MEFs in nudemice. Each cell type was injected into 16 mice and growth wasmonitored
for 3 weeks.
(C) Focus formation assay showing the effect of E1A/Ras overexpression in WT, DKO, p53+/ , DKO (p53+/ ), p53 / , and TKOMEFs. Cells were transduced with
E1A/Ras or vector control. The number of cells seeded (depending on the p53 status) is indicated (n = 3).
(D) Growth of E1A/Ras expressingMEFs from (C) in soft agar. The graphs indicate the differences in the number of colonies observed fromWT to DKOMEFs with
varying p53 status (p53+/+ [left], p53+/ [middle], or p53 / [right]). The number of colonies formed per 103 cells is indicated below each graph. Error bars indicate
SD (n = 3; independent sets of primary MEFs).
(E) Western blot analysis showing Ras levels in transformed MEFs used in (C) and (D). WB, western blot.
442 Cancer Cell 16, 439–446, November 3, 2009 ª2009 Elsevier Inc.
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et al., 2008). Given the negative regulation of Gas2 translation
by 4E-BPs, we asked whether Gas2 is necessary for the prema-
ture senescence in DKO MEFs. To this end, Gas2 expression
was silenced in DKO MEFs (passage 3) using Gas2-specific
shRNAs or a nonsilencing shRNA, shC. The varying degrees of
Gas2 reduction caused by the different shRNAs were paralleled
by similar reductions in p53 protein expression (Figure 3E). After
two passages, 17% of DKOMEFs expressing shC exhibited SA-
b-gal activity (Figure 3F). However, SA-b-gal activity was
reduced to 6% when Gas2 was silenced in DKO MEFs
(Figure 3F). Furthermore, Gas2-specific shRNAs caused an
increase in cell proliferation (2.1 ± 0.2, 4.3 ± 0.8, and 5.6 ± 1.0
PDs, p < 0.05, for the different Gas2 shRNAs) (Figure 3G). DKO
MEFs expressing shC shRNA underwent 1.9 ± 0.5 PDs
(Figure 3G). Importantly, each Gas2 shRNA promoted growth
Figure 3. Increased Gas2 mRNA Translation Causes Senescence in DKO MEFs
(A) Western blot analysis of p53, Gas2, and 4E BP1 levels in WT and DKO MEFs after serum stimulation. WB, western blot.
(B) Western blot analysis of Gas2 and 4E BP1 protein levels in p53 / and TKOMEFs after serum stimulation. a Tubulin served as a loading control in (A) and (B)
(results are representative of two independent experiments). WB, western blot.
(C) Shown in the upper panel is a graph representing the relative calpain activity in independent primary WT and DKO MEF extracts. Error bars indicate the SD
(n = 3). Shown in the lower panel is mean fluorescence representing calpain activity in WT (red) and DKO (blue) MEFs; the cleavage product was continuously
measured for 570 s (n = 3).
(D) Graphs showing the distribution of Gas2, p53, p19ARF, and b actin mRNA in sucrose gradients prepared from MEFs after 24 hr of serum stimulation. The
distribution of each mRNA, as determined using RT qPCR, is shown for WT (closed squares,-) and DKO MEFs (open circles,B).
(E) Western blot showing expression of Gas2 protein in DKO MEFs postsilencing by Gas2 shRNAs (shGas2#1, shGas2#2, shGas2#3) and control, shC. b actin
served as a loading control. WB, western blot.
(F) Graph showing%SA b gal positive cells in control cells (shC) or following silencing of Gas2 (shGas2#2 or shGas2#3) in DKOMEFs. Error bars indicate the SD
(n = 3).
(G) Population doublings (after four passages) for DKO MEFs transduced with shGas2#1, shGas2#2, shGas2#3, or shC.Cancer Cell 16, 439–446, November 3, 2009 ª2009 Elsevier Inc. 443
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These data demonstrate that 4E-BPs control p53-dependent
senescence by regulating Gas2 translation.
DISCUSSION
Aberrant translational control is a common feature in cancer
(Schneider and Sonenberg, 2007). Accordingly, eIF4E and its
4E-BP suppressors play an important role in malignant transfor-
mation. In this study we unveiled a mechanism of translational
control in cancer, which demonstrates a role for 4E-BPs in
p53-dependent tumorigenesis. Akin to 4E-BPs, tumor suppres-
sors, such as E2F, may exhibit context-dependent roles in
tumorigenesis (Yamasaki et al., 1998). We show that 4E-BPs
suppress p53-dependent senescence through the translational
repression of Gas2 mRNA (see model, Figure 4). Conversely, in
cells lacking p53, 4E-BPs inhibit neoplastic growth. Because
cells that lack 4E-BP expression have higher levels of Gas2
protein and undergo p53-dependent senescence, our findings
are consistent with a recent report demonstrating the require-
ment of p53 for Gas2-mediated growth inhibition (Kondo et al.,
2008).
Our finding that deletion of 4E-BPs in p53 knockout mice
reduces tumor-free survival may have important implications
for human disease. It was reported that lower amounts of 4E-
BP1 in childhood rhabdomyosarcoma (Petricoin et al., 2007) or
its inactivation through hyperphosphorylation in several cancers,
including ovarian (Armengol et al., 2007), breast (Rojo et al.,
2007), and melanoma (O’Reilly et al., 2009), are associated
with poor prognosis and survival. Thus, 4E-BPs may serve as a
cell proliferation ‘‘brake’’ in response to a deregulated p53
Figure 4. Model Showing the Control of p53 Dependent Senescence
by 4E BPs
4E BPs inhibit translation of Gas2 mRNA whose product stabilizes p53 by
bindingm calpain and inhibiting its protease activity. p53 induces senescence
and resistance to transformation. Induction of p53 may also cause transla
tional inhibition through 4E BP activation as a negative feedback mechanism
(Constantinou and Clemens, 2005, 2007). In the absence of 4E BPs, this nega
tive feedback mechanism is impaired.444 Cancer Cell 16, 439–446, November 3, 2009 ª2009 Elsevier Incpathway. p53 is also a regulator of metabolic stress (Murray-
Zmijewski et al., 2008), raising the possibility that p53 regulation
by 4E-BPs represents a homeostatic mechanism linking transla-
tion initiation to the p53 pathway. Such a role for 4E-BPs in this
context is supported by studies in Drosophila (Teleman et al.,
2005; Tettweiler et al., 2005).
Taken together, our findings indicate that a combination of p53
loss and heightened eIF4E activity (due to 4E-BP inactivation)
are synergistic in enhancing cell proliferation and tumorigenesis.
Although other oncogenic pathways may become engaged
upon a reduction in 4E-BP amounts, here we present genetic
evidence of how translation initiation and p53 converge in tumor-
igenesis.
EXPERIMENTAL PROCEDURES
Generation of 4E-BP1 / 4E-BP2 / p53 / Triple Knockout Mice
and Injection of Nude Mice
4E BP1 / 4E BP2 / DKO mice were previously described (Colina et al.,
2008; Le Bacquer et al., 2007). p53 / mice were obtained from Taconic
(P53N12 M homozygotes). DKO and p53 / mice were intercrossed for
4E BP1 / 4E BP2 / p53 / TKO mice generation. All mice were in the
C57BL/6 background. CD1 male nude mice (6 8 weeks old; Charles River
Laboratories) were injected subcutaneously with 1 3 106 cells in 100 ml phos
phate buffered saline. Animal protocols were approved by the McGill Univer
sity Animal Care Committee and in compliance toMcGill University guidelines.
Cell Lines, Preparation of Primary MEFs, Focus Formation,
Soft Agar Assays, and Cell Doubling Assays
MEFs were prepared as described (Le Bacquer et al., 2007). Primary MEFs
(between passages 2 and 8) were used. Early passage MRC5 fibroblasts
were obtained from American Type Culture Collection. Focus formation and
soft agar assays were performed as described (Lazaris Karatzas et al.,
1990). For cell doubling assay, MEFs were seeded at 6 3 105 cells/100 mm
dish and replated every 3 to 5 days. Cell numbers were determined by trypan
blue exclusion assays.
Polysomal RNA Preparation and Quantitative Polymerase
Chain Reaction
Polysomes were fractionated on sucrose density gradients and RNA was
extracted as described elsewhere (Mamane et al., 2007). Quantitative poly
merase chain reaction (qPCR) was performed as described previously (Marti
neau et al., 2008), using a Mastercycler ep realplex (Eppendorf) or CFX96
(Bio Rad). Quantification was performed using a standard curve derived
from serial dilutions of cDNA prepared from WT MEFs. Cycling conditions
and primer sequences are provided in Supplemental Data.
Plasmid Construction, Virus Production, Cell Sorting
4E BP cDNAswere subcloned into the BamH1/XhoI sites of the pMSCV IRES
GFP plasmid (gift from Jerry Pelletier). pLPC (empty control plasmid), pLPC
E1A, pLPC E1A/Ras, and p53shRNA retroviral vectors were gifts from Scott
Lowe. Retrovirus production was conducted as described (Le Bacquer
et al., 2007). GFP expressing cells were sorted using the FACS Vantage sorter
(BD Bioscience). shRNA lentiviruses were prepared as described with some
modifications (Stewart et al., 2003). Details are provided in the Supplemental
Experimental Procedures. Vectors targeting murine Gas2, human 4E BP1,
and human 4E BP2 were obtained from Sigma: TRCN0000088323
(shGas2#1), TRCN0000088324 (shGas2#2), TRCN0000088327 (shGas2#3),
TRCN0000040203 (shBP1), TRCN0000117814 (shBP2).
Antibodies
The following antibodies were used: anti p53 and anti 4E BP1 (Cell Signaling),
anti 4E BP2 (Banko et al., 2005), anti Gas2 (Abnova), anti p19ARF (Novus),
anti p16 (Santa Cruz), anti b actin and anti a tubulin (Sigma)..
Cancer Cell
4E-BPs Regulate Senescence and TransformationMeasurement of Calpain and SA-b-Galactosidase Activities
Calpain activity in vitro was measured using the InnoZyme Calpain1/2 Activity
Assay Kit (Calbiochem). Calpain activity in vivo was measured by flow cytom
etry with the substrate t BOC LM CMAC (t butoxycarbonyl Leu Met chloro
methylaminocoumarin) (Invitrogen), as described elsewhere (Niapour and
Berger, 2007). Cells were fixed and assayed for SA b gal activity as described
elsewhere (Dimri et al., 1995).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and
seven figures and can be found with this article online at http://www.cell.
com/cancer cell/supplemental/S1535 6108(09)00336 5.
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